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Abstract
Background The objective of the present study was to evalu-
ate the cost-utility of bariatric surgery in a lifetime horizon
from a Swedish health care payer perspective.
Methods A decision analytic model using theMarkov process
was developed covering cardiovascular diseases, type 2 dia-
betes, and surgical complications. Clinical effectiveness and
safety were based on the literature and data from the
Scandinavian Obesity Surgery Registry. Gastric bypass,
sleeve gastrectomy, and gastric banding were included in the
analysis. Cost data were obtained from Swedish sources.
Results Bariatric surgery was cost saving in comparison with
conservative management. It also led to a substantial reduction
in lifetime risk of events: from a 16 % reduction in the risk of
transient ischaemic attacks to a 62 % reduction in the incidence
of type 2 diabetes. Over a lifetime, surgery led to savings of
€8408 and generated an additional 0.8 years of life and 4.1
quality-adjusted life years (QALYs) per patient, which translates
into gains of 32,390 quality-adjusted person-years and savings
of €66 million for the cohort, operated in 2012. Analysis of the
consequences of a 3-year delay in surgery provision showed that
the overall lifetime cost of treatmentmay be increased in patients
with diabetes or a body mass index >40 kg/m2. Delays in sur-
gery may also lead to a loss of clinical benefits: up to 0.6 life
years and 1.2 QALYs per patient over a lifetime.
Conclusion Bariatric surgery, over a lifetime horizon, may
lead to significant cost savings to health care systems in addi-
tion to the known clinical benefits.
Keywords Bariatric surgery . Cost-utility analysis .
Cost-effectiveness analysis . Health economics . Cost .
Sweden
Introduction/Purpose
Obesity is a global epidemic. Considering the limited effec-
tiveness of conservative weight loss methods in severely
obese patients [1–3], bariatric surgery is the only available
treatment option. Because of the increased financial pressure,
there is an ongoing need to inform decision-makers and sur-
geons about the economic consequences of bariatric surgery
to health care systems in European countries. The objective of
the present study was to develop a comprehensive decision
analytic model for bariatric surgery to support decision-
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making for priority setting for the treatment of obesity in
European countries.
Patient Materials and Methods
Decision analytic modeling was employed to evaluate the
cost-effectiveness of bariatric surgery. A Markov process [4]
was developed covering surgery and post-surgery, post-
surgery complications, type 2 diabetes, angina pectoris, myo-
cardial infarction, stroke, transient ischaemic attack, heart fail-
ure, and peripheral arterial disease states. In theMarkovmodel
during each cycle, which is equal to 1 month, a patient may
progress to another health state (e.g., healthy individual in
post-surgery state may experience stroke) or remain in the
previous state. Each state is associated with specific cost and
utility (based on health-related quality of life). The flow of
patients in the surgical arm is presented in Fig. 1. The flow
of patients in the optimal medical management arm is the
same with the exception of absence of initial surgery, conver-
sion surgery, and surgical complications states. Cost-
effectiveness was evaluated over a lifetime perspective.
Additional information on methods is provided in section S1
of Supplemental Material.
Input Data
Clinical Effectiveness and Safety Data
The model operates by predicting the risk of cardiovascular
events, type 2 diabetes, and complications of surgery. The risk
of cardiovascular events is predicted by the patient’s charac-
teristics (age, gender, level of systolic blood pressure (SBP),
level of body mass index (BMI), presence of diabetes, and
smoking status), which can increase or decrease the risk of
events [5–9]. Short-term safety was informed by the
Michigan Bariatric Surgery Registry data [10, 11], and data
for long-term safety of surgery were based on information
from the Scandinavian Obesity Surgery Registry (SOREG)
[12]. Cholecystectomy, abdominal hernia repair, leakage and
abscess, gastric stricture, gastric ulcer, skin surgery, and con-
version surgery were considered.
The premise of the analysis is that the risk of cardiovascular
events and diabetes depends on multiple risk factors and, by
modifying some of these factors (BMI, SBP, presence of dia-
betes), the overall risk can be modified. By modeling the risk
in the surgical arm and in a hypothetical cohort of non-
operated patients, it is then possible to quantify the impact of
surgery on the rate of long-term adverse events.
Fig. 1 Structure of the Markov model. The figure presents the structure
of theMarkov model. Patients in the surgical arm enter the model through
the BInitial surgery^ state and, in the next cycle, move to either BDiabetes
post-surgery^ or BNo Diabetes post-surgery^ state depending on the
presence or absence of diabetes at the start of the analysis. Patients may
recover from diabetes or experience diabetes. From any of the post-
surgery state, patients can experience angina pectoris, myocardial infarc-
tion, heart failure, transient ischaemic attack, stroke, peripheral arterial
disease, complications of surgery, or undergo conversion surgery if
weight loss was not achieved. Patients can also move from one negative
health state to another (i.e., experience a stroke after being in a heart
failure state). Patients may also die from any state. Patients in the medical
management arm enter the model either through BDiabetes^ or BNo
diabetes^ state. They can experience the same negative events except
for complications of surgery or conversion surgery
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Three of the most common surgical approaches were in-
cluded into the model: gastric bypass (GBP), sleeve gastrec-
tomy (SG), and adjustable gastric banding (GB). Although
GB has a very limited utilization is Sweden, it was included
for comparative purposes. The relationship between the dif-
ferent surgical methods and the BMI level was derived from
SOREG 2011 data for base-case analysis [12]. Using the latest
follow-up observation available (2 years), the impact on the
BMI was extrapolated using data on BMI change from the
Swedish Obese Subjects (SOS) study [13]. After 15 years,
the BMI level was assumed stable for the rest of the patient’s
life. Changes in BMI in the optimal medical management arm
were derived from changes of BMI in the control arm of the
SOS study [13]. The major clinical inputs are presented in
Table 1 (additional inputs are presented in Table S1).
Resource Utilization and Cost Data
Cost data were determined using Swedish sources. The base-
case analysis included only direct medical costs.
The number of surgical procedures as well as the rate of use
of the different surgical methods (GBP—98 %, SG—1.6 %,
GB—0.4 %) were obtained from SOREG [12].
The costs of complications of obesity were obtained from
the literature [15–17, 19–21]. The major cost data are present-
ed in Table 1 (additional information in Table S1). For the
scenario analysis, the indirect cost of end-stage events was
added to the analysis. The cost data are presented in 2012
euros. The inflation adjustment of values in Swedish krona
was initially performed using the Swedish consumer price
index [22], and values were then, as recommended in the
literature [23], converted into euro currency (1 SEK=0.089
euro) using purchase power parities [24].
Utility Data
Health-related quality of life (HRQoL) was expressed on the
basis of the generic HRQoL instrument, EuroQol-5D (EQ-
5D), and was dependent on the BMI level and the presence
of diabetes [25]. The impact of complications of obesity on
quality of life was based on the literature [26]. Utility data are
presented in Table S1.
Cohort Description
Two types of cohorts were evaluated in the model. First, anal-
ysis in the so-called multiple cohorts was performed based on
a cohort of real candidates for surgery in Sweden.
Characteristics of patients for analysis were obtained from
SOREG [12], the SOS study [9], and the OECD data [14]
(Table 1). Second, the cost-effectiveness of bariatric surgery
was estimated in 16 cohorts of 41-year-old non-smoking
males and females with different BMI levels: 30–34
(moderate), 35–39 (severe), 40–50 (morbid), and >50 kg/m2
(super obese). Further sub-classification was made for the
presence or absence of type 2 diabetes.
Analysis
The incremental cost-effectiveness ratio (ICER) was cal-
culated by comparing the difference in the average total
costs with the difference in the average quality-adjusted
life years (QALYs) among the study’s arms. All costs and
outcomes beyond the first year were discounted at the rate
of 3.0 % annually according to Swedish recommendations
[27]. The intervention was considered cost-effective if the
ICER was below €35,526 per QALY [28–30]. It means
that to be considered cost-effective in Sweden, medical
technology needs to lead to additional cost of no more
than €35,526 for one extra year of life of full health
(QALY).
In addition to the standard evaluation of cost-effectiveness
between two treatment options, an analysis was performed on
the impact of waiting lists (delay in surgery provision) on the
clinical and economic outcomes. The patients were initially
included in the optimal medical management arm and then
moved to the surgical arm after 3 years. The results were
compared with those of patients who underwent immediate
surgery.
The model was constructed using Microsoft Excel 2010
(Microsoft Corp., Redmond, WA, USA) and was extensively
validated with results provided in Supplementary material.
Sensitivity and Scenario Analysis
A one-way deterministic sensitivity analysis was performed to
assess the impact of varying the model parameters while hold-
ing other variables fixed at base-case values. In addition to a
one-way sensitivity analysis, 11 additional scenarios were
tested (Section S3). To address sampling uncertainty, a prob-
abilistic sensitivity analysis (PSA) was performed using 5000
Monte Carlo simulations. In PSA, specific distribution (i.e.,
normal, log-normal, beta, gamma, and uniform) is determined
for every parameter; during 5000 runs (simulations) each pa-
rameter varies randomly within a pre-specified distribution.
The outcomes of interest (cost, life years gained, and
QALYs gained) are averaged across 5000 runs.
Results
Model Validation
The external validation showed that the model predicts the
majority of clinical events (cardiovascular mortality, stroke,
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health failure, angina, peripheral arterial disease, incidence
and remission of diabetes) with a high degree of precision,
although there was a tendency to overestimate all-cause mor-
tality and combined (fatal and non-fatal) myocardial infarc-
tion. Details of the validation and evaluation of the model’s
performance are presented in Section S2.
Base-Case Results in Multiple Cohorts Extrapolated
from SOS and SOREG
In the base-case analysis, bariatric surgery was cost saving in
comparison with conservative management. In the simulation,
surgery led to substantial reduction in the lifetime risk of
Table 1 Major clinical, cost, and utility inputs
Parameter Value Range Distribution for probabilistic
sensitivity analysis
Source
Patient baseline characteristic
Age, years 41 25–65 Normal (SD=5) SOREG 2011 [12]
Gender, males (%) 24 NA Beta (α=1760; β=5874)
Body mass index, kg/m2 42.8 30–60 Normal (SE=5.8)
Diabetes mellitus, (%) 18.39 NA Beta (α=1404; β=6230)
Systolic blood pressure, mmHg 140.1 125–200 Gamma (α=55.53; λ=2.52) Sjostrom 2004 [9]
Smoking, (%) 14.3 NA Beta (α=1128; β=6770) OECD fact book [14]
Absolute BMI reduction, reported in the Scandinavian Obesity Surgery Registry
GBP, 1-year, males 12.7 8.7–37.7 Normal (SD=2.2) SOREG 2011 [12]
GBP, 2-year, males 12.6 8.6–37.4 Normal (SD=2.2)
SG, 1-year, males 9.7 5.9–25.5 Normal (SD=1.7)
SG, 2-year, males 9.4 5.7–24.7 Normal (SD=1.6)
GB, 1-year, males 5.6 3.9–16.9 Normal (SD=1.0)
GB, 2-year, males 6.9 4.8–20.9 Normal (SD=1.2)
GBP, 1-year, females 13.5 9.5–41.1 Normal (SD=2.4)
GBP, 2-year, females 13.5 9.5–41.2 Normal (SD=2.4)
SG, 1-year, females 12.5 7.5–32.8 Normal (SD=2.2)
SG, 2-year, females 14.7 8.9–38.0 Normal (SD=2.6)
GB, 1-year females 5.5 3.9–17.0 Normal (SD=0.9)
GB, 2-year, females 5.1 3.6–15.7 Normal (SD=0.9)
Other clinical inputs
Proportion of patients with remission of
diabetes at 2 years, surgical arm
0.72 0.67–0.77 Beta (α=246; β=95) Sjostrom 2004 [9]
Proportion of patients with remission of
diabetes at 2 years, OMM arm
0.21 0.15–0.27 Beta (α=52; β=196)
Proportion of patients with remission of
diabetes at 10 years, surgical arm
0.36 0.25–0.50 Beta (α=42; β=76)
Proportion of patients with remission of
diabetes at 10 years, OMM arm
0.13 0.07–0.22 Beta (α=11; β=73)
Cost inputs, €
Cost of bariatric surgery without complications 4915 3932–5898 NA NordDRG tariff L08E
Cost of bariatric surgery with complications 5766 4613–6919 NA NordDRG tariff L08C
Annual cost of diabetes type 2 2713 1356–5426 Gamma (α=100; λ=305) Henriksson 2000 [15]
Annual cost of acute stroke 7532 3766–15,063 Gamma (α=100; λ=848) Ghatnekar 2004 [16]
Annual cost of post-stroke 1 year 7779 3889–15,558 Gamma (α=100; λ=875)
Annual cost of post-stroke 2 year and onwards 5784 2892–11,569 Gamma (α=100; λ=651)
Cost of transient ischemic attack 1928 1542–1851 NA NordDRG DRG tariff A47N
Cost of acute myocardial infarction 4592 2296–9183 Gamma (α=100; λ=516) Henriksson 2011 [17]
Annual cost of post-MI state 3590 1795–7181 Gamma (α=100; λ=404) Wilhelmsen 2010 [18]
Annual cost of heart failure 3895 1947–7790 Gamma (α=100; λ=438) Agvall 2005 [19]
Annual cost of peripheral artery disease 4013 2006–8026 Gamma (α=100; λ=451) Levy 2003 [20]
Annual cost of angina pectoris 4055 2027–8109 Gamma (α=100; λ=456) Andersson 1995 [21]
GB gastric banding, GBP gastric bypass, MI myocardial infarction, OMM optimal medical management, SG sleeve gastrectomy
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negative events (Table 2), from a 16 % reduction in the risk of
transient ischaemic attack to a 62% reduction in the incidence
of type 2 diabetes. Over the lifetime of the cohort, surgery led
to savings of €8408 and generated an additional 0.8 years of
life or 4.1 QALYs per patient (Table 3). In Swedish settings,
bariatric surgery becomes cost-effective (i.e., even though sur-
gery may have higher cost, it leads to more benefits, and cost/
effect ratio is thus below accepted willingness-to-pay thresh-
old in Sweden) after 2 years (ICER €26,985/QALY) and cost
saving (i.e., surgery leads to more benefits at lower cost) after
17 years (Figure S5).
Results in Specific Cohorts of Patients
Analysis in specific cohorts revealed that bariatric surgery is
cost saving in all of the four pre-specified diabetic cohorts
(moderately, severely, morbidly, and super obese) in both
male and female patients. In the non-diabetic cohorts, surgery
was cost saving in all cohorts except for moderately obese
male (ICER €459/QALYs) and female (ICER €51/QALYs)
patients. In these two cohorts, surgery remained very cost-
effective (well below the willingness-to-pay threshold of
€35,526/QALYs). Detailed results are provided in
Tables S9-12. The degree of clinical benefits for the male
and female cohorts is outlined in Fig. S6A-B.
Impact of Waiting Lists on the Clinical and Economic
Outcomes of Bariatric Surgery
The analysis of the consequences of a 3-year delay in provid-
ing surgery showed that the overall lifetime cost in the surgical
arm may be slightly reduced in non-diabetic patients with
moderate and severe obesity (BMI<40 kg/m2), but the cost
was increased in non-diabetic patients with morbid or super
obesity and diabetic patients (increase from €23 to €2 803)
(Table 4, additional data in Table S13). Time delay in surgery
led to significant losses of clinical benefits (in the range of 0
and 0.6 for life years and 0.2 and 1.2 for QALYs). Losses of
clinical benefits are higher in males and diabetic patients.
Sensitivity Analyses
Deterministic one-way sensitivity analysis showed that four
parameters can affect the cost saving effect of surgery (i.e.,
surgery becomes cost-effective): (1) the magnitude of the ef-
fect of surgery, (2) start age (better to operate patients when
they are younger), (3) BMI (better to operate patients when
BMI is lower), and (4) inclusion of an annual visit to a surgeon
during the follow-up program from year three and onwards.
Change of cost variables with 50 % variations did not influ-
ence the cost saving effect of surgery. The most sensitive
parameter from cost variables was the annual cost of type 2
diabetes.
The probabilistic sensitivity analysis demonstrated that bar-
iatric surgery produces clinical benefits (additional QALYs) in
all patients and has a cost saving effect in 99.1 % of cases
while, in the remaining 0.9 %, it is cost-effective (Fig. 2).
Additional 11 scenario analyses showed that uncertainty
around the model inputs and structure did not affect the main
results significantly (Section S4).
Discussion
The present study examines economic consequences of bar-
iatric surgery in patients with severe obesity. As health care
systems are operating under significant resource constraints, it
Table 2 Number of events and relative risks over lifetime
Angina MI total non-fatal Fatal MI Stroke total non-fatal Fatal stroke TIA HF PAD Diabetes
Absolute risk in surgical arm 11 % 22 % 2 % 18 % 3 % 2 % 15 % 10 % 14 %
Absolute risk in OMM arm 13 % 28 % 3 % 23 % 4 % 2 % 19 % 11 % 36 %
Relative risk 0.82 0.80 0.70 0.79 0.78 0.84 0.84 0.84 0.38
HF heart failure, MI myocardial infarction, OMM optimal medical management, PAD peripheral artery disease, TIA transient ischemic attack
Table 3 Results of cost-effectiveness analysis
Cost, € Δ cost, € LYG, years Δ LYG QALYs gained Δ QALYs ICER, €/QALY
OMM arm 34,665 − 21.4 − 9.4 − −
Surgical arm 26,258 −8408 22.2 0.8 13.5 4.1 Dominates
Table presents results of cost-effectiveness analysis. Results demonstrate that surgery leads to lower cost and higher health gains compared with non-
surgical management, so surgery dominates over conservative management
ICER incremental cost-effectiveness ratio, LYG life years gained, OMM optimal medical management, QALYs quality-adjusted life years
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is important to ensure that health interventions are
either aiming to reduce the cost of care or provide good value
(clinical benefits) for the money spent (i.e., technologies are
cost-effective). Like all other health interventions, bariatric
surgery can be evaluated from an economic perspective to
support decision-making about the appropriateness of funds
allocation for this service.
In the present analysis, a decision analytic technique with
Markov modeling was used to evaluate the long-term eco-
nomic impact of surgery in the context of the Swedish health
care system. Decision analytic modeling is a well-established
approach in health economics [4, 23, 31] and is recognized by
health technology assessment bodies around the world
[32–34] and is included into the standard procedures for the
assessment of cost-effectiveness of technologies over a long
time horizon. Markov modeling was used in the vast majority
of the previous decision analytic models in the field of bariat-
ric surgery [7, 25, 35–42].
This cost-effectiveness analysis showed, in Swedish set-
tings, that bariatric surgery has a cost saving effect on the
Table 4 Impact of 3-year delay in surgery provision on total cost of treatment, life years, and QALYs gained in different cohorts of patients
Population Moderately obese Severely obese Morbidly obese Super obese
Males Females Males Females Males Females Males Females
Difference in total cost, €
Non-diabetic −437 −448 −439 −467 26 −6 196 170
Diabetic 2145 2708 2062 2625 2299 2803 2066 2551
Difference in life years gained
Non-diabetic −0.1 0 −0.2 −0.1 −0.2 −0.1 −0.2 −0.1
Diabetic −0.6 −0.1 −0.6 0 −0.6 0 −0.6 −0.1
Difference in quality-adjusted life years gained
Non-diabetic −0.3 −0.2 −0.3 −0.3 −0.6 −0.5 −0.8 −0.7
Diabetic −0.7 −0.4 −0.7 −0.4 −1 −0.6 −1.2 −0.8
Table presents modeled difference in cost and clinical outcomes between delayed and immediate surgery. Negative cost value indicates that delayed
surgery leads to reduction of cost compared with immediate surgery. Positive cost value indicates that delayed surgery leads to increased cost compared
with immediate surgery. Negative value of life years or QALYs gained indicates that delayed surgery leads to reduction of health benefits. For example,
in moderately obese diabetic males, delayed surgery will lead to increase of cost of €2 145 and loss of 0.6 life years or 0.7 QALYs
Fig. 2 Cost-effectiveness acceptability plane. The figure shows results of
probabilistic sensitivity analysis at the lifetime horizon. Each dot
represents results (change in cost and QALYs) for one simulated
patient. The figure presents two populations which differ by the
presence or absence of diabetes mellitus at the start of the model
(diabetic patients have a higher level of cost saving). Analysis shows
that bariatric surgery leads to additional benefits (increase in QALYs) in
all patients, and cost saving (lower cost compared with continuation of
optimal medical treatment) in majority of patients
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health care system over the patient’s lifetime and is associated
with substantial clinical benefits. If these clinical benefits are
extrapolated to the entire population of Swedish patients who
underwent surgery in 2012 (n=7900 from a population of
around nine million people), it would result in a gain of
6320 person-years or 32,390 quality-adjusted person-years.
Over the lifetime of the treated cohort, the Swedish health care
system will save up to €66 million. Both amounts of cost
savings and additional life years/QALYs over lifetime are pro-
vided after discounting at 3 % rate annually. This is in line
with standard methodology in health economics [4, 23, 31]
and Swedish recommendations [27], and it is used to reflect
important phenomena of patients valuing immediate benefits
more, than benefits in the future. When no discounting is
applied, expected benefits and cost saving are even greater
(Table S14). The results of the analysis were stable in multiple
sensitivity and scenario analyses including usage of very con-
servative estimate of the effect of surgery on BMI from recent
systematic literature review and network meta-analysis [44].
In addition to the ability to save cost to the health care
system over the lifetime of the patients, bariatric surgery was
shown to be cost-effective already 2 years after procedure.
Although decision-makers in Sweden and other European
countries usually require long enough time horizon for analy-
sis to capture all clinical and economic consequences of inter-
vention, ability to rapidly demonstrate good value for money
can support implementation of surgery among private payers/
insurers.
Our analysis is the first attempt to quantify the potential
impact of extensive waiting lists on the cost and clinical out-
comes of bariatric surgery in Sweden. While it indicates the
importance of reducing waiting time, few studies have specif-
ically focused on this parameter [43, 45, 46]. Results of the
present study highlight the necessity to reduce waiting lists
and to remove unnecessary barriers to allow a greater utiliza-
tion of surgery for patients unresponsive to conventional med-
ical management.
The analysis also showed that gastric bypass remains the
most economically beneficial surgical option. Although gas-
tric bypass is the dominant treatment option in Sweden, we
have tested a number of hypothetical scenarios of reduction of
use of gastric bypass and corresponding increase of use of
sleeve gastrectomy and adjustable gastric banding.
Reduction of proportion of gastric bypass from 98 to 60 %
will result in a loss of €1156 and 0.6 QALYs per patient and,
for the patient population who underwent surgery in 2012, it
represents loss of €9.1 million and 2844 QALYs for the life-
time of the cohort.
Our analysis is based on a comprehensive decision analytic
model, which had both internal technical and external valida-
tion against three large clinical studies and the Scandinavian
Obesity Surgery Registry. The present study extends the al-
ready existing body of evidence on the economic impact of
surgery either derived from decision analysis modeling [7, 25,
35–40, 47–49] or real-world economic analyses [50–57]. Our
results are in agreement with the overall estimates from other
analyses. These studies have either shown the cost saving
effect of surgery or its very high cost-effectiveness, which
places bariatric surgery in a preferable position when health
care priorities have to be established.
Another interesting finding of the analysis is negligible
impact of increase of proportion of high-volume centers on
cost of surgery over lifetime of patients (Figures S7 and S8).
Although improved quality of care may have important short-
term costs and clinical outcomes, over the lifetime of the co-
hort, it does not play an important role, as key cost drivers are
cost of long-term complications of surgery.
The study has a number of limitations. First, we acknowl-
edge that every decision analytic model is a simplification of
true health care systems and ideal source of information about
cost and clinical benefits of comparative treatment strategies
should be derived from randomized controlled trials (RCTs).
Nevertheless, in situations where there is a lack of RCTs with
appropriate comparators, duration of follow-up, and compre-
hensive data collection, modeling is inevitable. Second, our
model does not include all potential obesity-related diseases
(obstructive sleep apnea, musculoskeletal disorders, cancer,
obstetrics and gynecology disorders) for which clinical evi-
dence of the beneficial effect of bariatric surgery is emerging.
The inclusion of these health states may further increase its
cost benefit. Third, our model does not distinguish between
the different populations of diabetic patients who may have
better or worse outcomes of surgical intervention as reported
in a number of recent studies [58–60]. Fourth, the current
surgical and conventional management approaches may differ
from those used in the studies that provided the major data
inputs (i.e., SOS study). Fifth, the utilization of sleeve gastrec-
tomy and gastric banding is very limited in Sweden. Thus, the
extrapolation of our results to countries with a higher utiliza-
tion of these two procedures may be limited. Sixth, data about
routine pre- and post-surgery as well as routine conservative
management of surgical candidates in Sweden were limited,
so assumptions were required. As it was shown in the sensi-
tivity analysis, the cost of routine post-surgery care may influ-
ence the cost-effectiveness of bariatric surgery.
In conclusion, using a comprehensive decision analytic
model over the patient’s lifetime, we have shown that bariatric
surgery is associated with significant clinical benefits that lead
to cost savings to the health care system.
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